2026-06-27T23:16:19Zhttps://docta.ucm.es/rest/oai/request
oai:docta.ucm.es:20.500.14352/180632024-09-02T15:07:01Zcom_20.500.14352_14col_20.500.14352_15
Docta Complutense author Andrés Guerrero, Vanesa author Perucho González, Lucía author García Feijoo, Julián author Morales Fernández, Laura author Sáenz Francés, Federico author Herrero Vanrell, María Del Rocío author Pablo Júlvez, Luis author Polo Llorens, Vicente author Martínez De La Casa Fernández-Borrella, José María author Konstas, Anastasios Georgios P. 2023-06-17T22:06:04Z 2023-06-17T22:06:04Z 2017-02 Andrés Guerrero, V., Perucho González, L., García Feijoo, J. et al. «Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma». Advances in Therapy, vol. 34, n.o 2, febrero de 2017, pp. 378-95. Springer Link, https://doi.org/10.1007/s12325-016-0461-z. 0741-238X 10.1007/s12325-016-0461-z https://hdl.handle.net/20.500.14352/18063 https://dx.doi.org/10.1007%2Fs12325-016-0461-z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331081/https://link.springer.com/article/10.1007%2Fs12325-016-0461-z The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments. eng Atribución-NoComercial 3.0 España Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma journal article URL https://docta.ucm.es/bitstreams/c8767cec-949c-4939-bd79-52fa0df19807/download File MD5 e5917672a337bcf5e3c18bd610e06fc5 695147 application/pdf use anti-VEGF-advancestherap-2017.pdf